Table 4.
Prescribed medications for asthma
| Study population N = 101 |
|
|---|---|
| OCS |
N (%) 20 (19.8%) |
| Corticosteroids burst treatment/short course |
N (%) 79 (78.2%) |
| ICS/LABA |
N (%) 101 (100.0%) |
| Active substances | N (%) |
| Budesonide/Formoterol | 57 (56.4%) |
| Fluticasone/Salmeterol | 17 (16.8%) |
| Fluticasone/Vilanterol | 8 (7.9%) |
| Beclomethasone/Formoterol | 7 (6.9%) |
| Other | 12 (11.9%) |
| Total daily ICS dose | N = 100 |
| Low dose | 0 (0.0%) |
| Medium dose | 34 (34.0%) |
| High dose | 66 (66.0%) |
| Time since initiation of ICS/LABA, in years | |
| Mean ± SD | 4.5 ± 4.3 |
| Range | 0–19.2 |
| Median | 2.9 |
| N = 82 | |
| Other maintenance treatments | N (%) |
| Leukotriene receptor antagonists | 58 (70.7%) |
| Anticholinergics | 36 (43.9%) |
| Glucocorticoids | 27 (32.9%) |
| Systemic anti-histamines | 20 (24.4%) |
ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; OCS: chronic oral corticosteroids; SD: standard deviation